=> d his

(FILE 'HOME' ENTERED AT 13:58:36 ON 01 MAR 2005)

FILE 'USPATFULL' ENTERED AT 13:58:50 ON 01 MAR 2005
L1 249 S ((NATRIURETIC (W) (RECEPTOR OR PEPTIDE)) OR ANP OR BNP) AND (
L2 10 S (((NATRIURETIC (W) (RECEPTOR OR PEPTIDE)) OR ANP OR BNP) AND

=> d bib,kwic 1-10

L2 ANSWER 1 OF 10 USPATFULL on STN
AN 2004:269406 USPATFULL
TI Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (CALSARCINS)
IN Olson, Eric, Dallas, TX, UNITED STATES
Frey, Norbert, Dallas, TX, UNITED STATES
PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2004210950 A1 20041021
AI US 2004-760111 A1 20040116 (10)
RLI Division of Ser. No. US 2001-45594, filed on 7 Nov 2001, PENDING
PRAI US 2000-246629P 20001107 (60)
DT Utility
FS APPLICATION
LREP Steven L. Highlander, FULBRIGHT & JAWORSKI L.L.P., 600 Congress Avenue, Austin, TX, 78701
CLMN Number of Claims: 105
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 4400
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:
. . . chain-2 promoter, α actin promoter, troponin I promoter, Na.sup.+/Ca.sup.2+ exchanger promoter, dystrophin promoter, creatine kinase promoter, α7 integrin promoter, brain **natriuretic peptide** promoter, α B-crystallin/small heat shock protein promoter, α myosin heavy chain promoter or atrial natriuretic factor promoter.

84. A method of treating **cardiac hypertrophy**, heart failure or Type II diabetes comprising the step of administering to an animal suffering therefrom a calsarcin polypeptide, or. . .
85. A method of treating **cardiac hypertrophy**, heart failure or Type II diabetes, comprising the step of administering to an animal suffering therefrom a nucleic acid encoding. . .

L2 ANSWER 2 OF 10 USPATFULL on STN
AN 2004:240460 USPATFULL
TI Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
IN Olson, Eric, Dallas, TX, UNITED STATES
Frey, Norbert, Dallas, TX, UNITED STATES
PA Board of Regents, The University of Texas System. (U.S. corporation)
PI US 2004186275 A1 20040923
AI US 2004-759897 A1 20040116 (10)
RLI Division of Ser. No. US 2001-45594, filed on 7 Nov 2001, PENDING
PRAI US 2000-246629P 20001107 (60)
DT Utility
FS APPLICATION
LREP Steven L. Highlander, Esq., FULBRIGHT & JAWORSKI L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701
CLMN Number of Claims: 105
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 4402
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:
. . . chain-2 promoter, α actin promoter, troponin 1 promoter, Na.sup.+/Ca.sup.2+ exchanger promoter, dystrophin promoter, creatine

kinase promoter, α7 integrin promoter, brain **natriuretic peptide** promoter, α B-crystallin/small heat shock protein promoter, α myosin heavy chain promoter or atrial natriuretic factor promoter.

84. A method of treating **cardiac hypertrophy**, heart failure or Type II diabetes comprising the step of administering to an animal suffering therefrom a calsarcin polypeptide, or. . .
85. A method of treating **cardiac hypertrophy**, heart failure or Type II diabetes, comprising the step of administering to an animal suffering therefrom a nucleic acid encoding. . .

L2 ANSWER 3 OF 10 USPATFULL on STN
AN 2004:166196 USPATFULL
TI Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
IN Olson, Eric, Dallas, TX, UNITED STATES
Frey, Norbert, Dallas, TX, UNITED STATES
PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2004127686 A1 20040701
AI US 2004-759624 A1 20040116 (10)
RLI Division of Ser. No. US 2001-45594, filed on 7 Nov 2001, PENDING
PRAI US 2000-246629P 20001107 (60)
DT Utility
FS APPLICATION
LREP Steven L. Highlander, Esq., FULBRIGHT & JAWORSKI L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701
CLMN Number of Claims: 105
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 4400
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:
. . . chain-2 promoter, α actin promoter, troponin 1 promoter, Na.sup.+/Ca.sup.2+ exchanger promoter, dystrophin promoter, creatine kinase promoter, α7 integrin promoter, brain **natriuretic peptide** promoter, α B-crystallin/small heat shock protein promoter, α myosin heavy chain promoter or atrial natriuretic factor promoter.

84. A method of treating **cardiac hypertrophy**, heart failure or Type II diabetes comprising the step of administering to an animal suffering therefrom a calsarcin polypeptide, or. . .
85. A method of treating **cardiac hypertrophy**, heart failure or Type II diabetes, comprising the step of administering to an animal suffering therefrom a nucleic acid encoding. . .

L2 ANSWER 4 OF 10 USPATFULL on STN
AN 2004:114081 USPATFULL
TI STARS - a muscle-specific actin-binding protein
IN Olson, Eric, Dallas, TX, UNITED STATES
Arai, Akiko, Mie, JAPAN
PA Board of Regents,The University of Texas System (U.S. corporation)
PI US 2004086920 A1 20040506
AI US 2003-644659 A1 20030820 (10)
PRAI US 2002-404706P 20020820 (60)
DT Utility
FS APPLICATION
LREP Steven L. Highlander, FULBRIGHT & JAWORSKI L.L.P., 600 Congress Avenue, Suite 2400, Austin, TX, 78701
CLMN Number of Claims: 105
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 5069
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:
. . . chain-2 promoter, α actin promoter, troponin 1 promoter, Na.sup.+/Ca.sup.2+ exchanger promoter, dystrophin promoter, creatine

kinase promoter, α7 integrin promoter, brain **natriuretic peptide** promoter, αB-crystallin/small heat shock protein promoter, α myosin heavy chain promoter and atrial natriuretic factor promoter.

80. A method of treating **cardiac hypertrophy** and dilated cardiomyopathy comprising decreasing STARS activity in heart cells of a subject.

90. A method of preventing **cardiac hypertrophy** and dilated cardiomyopathy comprising decreasing STARS activity in heart cells of a subject.

91. A method of inhibiting progression of **cardiac hypertrophy** comprising decreasing STARS activity in heart cells of a subject.

94. A method of increasing exercise tolerance in a subject with heart failure or **cardiac hypertrophy** comprising decreasing STARS activity in heart cells of a subject.

95. A method of reducing hospitalization in a subject with heart failure or **cardiac hypertrophy** comprising decreasing STARS activity in heart cells of a subject.

96. A method of improving quality of life in a subject with heart failure or **cardiac hypertrophy** comprising decreasing STARS activity in heart cells of a subject.

97. A method of decreasing morbidity in a subject with heart failure or **cardiac hypertrophy** comprising decreasing STARS activity in heart cells of a subject.

98. A method of decreasing mortality in a subject with heart failure or **cardiac hypertrophy** comprising decreasing STARS in heart cells of a subject.

L2 ANSWER 5 OF 10 USPATFULL on STN
AN 2003:314710 USPATFULL
TI Transgenic mouse model for cardiac hypertrophy and methods of use thereof
IN Grant, Stephen R., Ft. Worth, TX, United States
Olson, Eric N., Dallas, TX, United States
Molkentin, Jeffrey D., Cincinnati, OH, United States
PA Texas Systems, University of the Board of the Regents, Austin, TX, United States (U.S. corporation)
University of North Texas Health Science Center, Fort Worth, TX, United States (U.S. corporation)
PI US 6657104 B1 20031202
AI US 1998-173799 19981015 (9)
RLI Continuation of Ser. No. US 1998-61417, filed on 16 Apr 1998
PRAI US 1998-81853P 19980415 (60)
US 1997-65178P 19971110 (60)
US 1997-62864P 19971016 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Clark, Deborah J. R.; Assistant Examiner: Baker, Anne-Marie
LREP Fulbright & Jaworski
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 54 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 3167
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:
. . . or a functional fragment of calcineurin or CaMKIV in said transgenic mouse results in an increased probability of spontaneously developing

cardiac hypertrophy when compared to a non-transgenic littermate.

. . . said foster mother mouse, wherein said transgenic mouse is characterized in that it has an increased probability of spontaneously developing **cardiac hypertrophy** when compared to a non-transgenic littermate.

13. A method for screening a substance for the ability to reduce **cardiac hypertrophy** comprising: a) administering the substance to the transgenic mouse of claim 1; b) measuring a **cardiac hypertrophy** parameter in the mouse of step (a) c) comparing the measurement obtained in step (b) to that of a transgenic littermate not administered the substance, wherein the measurement of the **cardiac hypertrophy** parameter in the mouse of step (a) is consistent with a reduction in **cardiac hypertrophy**.

14. The method according to claim 13, wherein the **cardiac hypertrophy** parameter is expression of a gene selected from the group consisting of an atrial natriuretic factor gene, a b-type **natriuretic peptide** gene, a β-myosin heavy chain gene, and an α-skeletal actin gene.

L2 ANSWER 6 OF 10 USPATFULL on STN
AN 2003:213658 USPATFULL
TI Differential gene expression in cardiac hypertrophy
IN Brown, Harlan Roger, Durham, NC, UNITED STATES
Mansfield, Traci Ann, Guilford, CT, UNITED STATES
PI US 2003148296 A1 20030807
AI US 2002-106691 A1 20020326 (10)
PRAI US 2001-280048P 20010330 (60)
DT Utility
FS APPLICATION
LREP DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 1815
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:
1. A method of screening a compound for effects on cardiac muscle, comprising: (a) administering a test compound to a. . . of a gene selected from the group consisting of uncoupling protein 1 (UCP1), cytosolic malic enzyme, and atrial natriuretic factor (**ANP**); where increased expression of said gene in the test animal, compared to expression that would occur in a control animal, indicates said compound induces **cardiac hypertrophy**.

. . . said gene in the test animal, compared to expression that would occur in a control animal, indicates said compound induces **cardiac hypertrophy**.

7. A method of diagnosing **cardiac hypertrophy** in an animal, comprising: (a) obtaining a sample of heart tissue from said animal; and (b) determining at least one. . . of a gene selected from the group consisting of uncoupling protein 1 (UCP1), cytosolic malic enzyme, and atrial natriuretic factor (**ANP**) is increased compared to normal levels of expression; (iii) whether the level of expression of a gene selected from the. . .

L2 ANSWER 7 OF 10 USPATFULL on STN
AN 2003:207815 USPATFULL
TI Methods and compositions relating to MEK5 and cardiac hypertrophy and dilated cardiomyopathy
IN Olson, Eric N., Dallas, TX, UNITED STATES

Nicol, Rebekka, Hicksville, NY, UNITED STATES
PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2003144176 A1 20030731
AI US 2002-159971 A1 20020530 (10)
PRAI US 2001-295875P 20010604 (60)
DT Utility
FS APPLICATION
LREP STEVEN L. HIGHLANDER, FULBRIGHT & JAWORSKI L.L.P., SUITE 2400, 600 CONGRESS AVENUE,, AUSTIN, TX, 78701-3271
CLMN Number of Claims: 64
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 3743
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:

1. A method for inhibiting **cardiac hypertrophy** in a subject comprising administering to said subject an amount of a composition effective to inhibit MEK5 activity, whereby inhibition of MEK5 activity inhibits **cardiac hypertrophy**.

. . . troponin 1 promoter, the Na.sup.+/Ca.sup.2+ exchanger promoter, the dystrophin promoter, the creatine kinase promoter, the alpha7 integrin promoter, the brain **natriuretic peptide** promoter, the α B-crystallin/small heat shock protein promoter, α myosin heavy chain promoter and the ANF promoter.

41. A method of screening for an inhibitor of **cardiac hypertrophy** comprising: (a) providing a cell comprising a MEK5 coding region under the control of a promoter, wherein MEK5 is expressed. . . candidate inhibitor substance, indicates that said candidate inhibitor substance is an inhibitor of MEK5 activity, and hence, an inhibitor of **cardiac hypertrophy**.

48. The method of claim 41, wherein said determining comprises measuring MEK5-induced **cardiac hypertrophy** signaling.

51. The method of claim 43, wherein said determining comprises measuring **cardiac hypertrophy**, or a symptom thereof.

52. The method of claim 51, wherein said **cardiac hypertrophy** symptom is selected from the group consisting of hypertrophic or fetal gene expression, fibrosis, reduced cardiac contractility, or increased heart/body,. . .

L2 ANSWER 8 OF 10 USPATFULL on STN
AN 2003:113635 USPATFULL
TI Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
IN Olson, Eric, Dallas, TX, UNITED STATES
Frey, Norbert, Dallas, TX, UNITED STATES
PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2003078376 A1 20030424
AI US 2001-45594 A1 20011107 (10)
PRAI US 2000-246629P 20001107 (60)
DT Utility
FS APPLICATION
LREP Steven L. Highlander, Fulbright & Jaworski L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701
CLMN Number of Claims: 105
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 4067
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:

. . . chain-2 promoter, α actin promoter, troponin 1 promoter, Na.sup.+/Ca.sup.2+ exchanger promoter, dystrophin promoter, creatine kinase promoter, α7 integrin promoter, brain **natriuretic peptide** promoter, α B-crystallin/small heat shock protein

promoter, α myosin heavy chain promoter or atrial natriuretic factor promoter.

84. A method of treating **cardiac hypertrophy**, heart failure or Type II diabetes comprising the step of administering to an animal suffering therefrom a calsarcin polypeptide, or. . .

85. A method of treating **cardiac hypertrophy**, heart failure or Type II diabetes, comprising the step of administering to an animal suffering therefrom a nucleic acid encoding. . .

L2 ANSWER 9 OF 10 USPATFULL on STN
AN 2003:113077 USPATFULL
TI CHAMP - a novel cardiac helicase-like factor
IN Olson, Eric, Dallas, TX, UNITED STATES
Liu, Zhi-Ping, Dallas, TX, UNITED STATES
PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2003077810 A1 20030424
AI US 2002-77583 A1 20020215 (10)
PRAI US 2001-269764P 20010216 (60)
US 2002-351713P 20020124 (60)
DT Utility
FS APPLICATION
LREP Steven L. Highlander, FULBRIGHT & JAWORSKI L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701
CLMN Number of Claims: 112
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 5276
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:
. . . chain-2 promoter, alpha actin promoter, troponin 1 promoter, Na.sup.+/Ca.sup.2+ exchanger promoter, dystrophin promoter, creatine kinase promoter, alpha7 integrin promoter, brain **natriuretic peptide** promoter, alpha B-crystallin/small heat shock protein promoter, alpha myosin heavy chain promoter and atrial natriuretic factor promoter.

86. A method of treating **cardiac hypertrophy** comprising increasing CHAMP activity in heart cells of a subject.

87. A method of preventing **cardiac hypertrophy** comprising increasing CHAMP activity in heart cells of a subject.

88. A method of inhibiting progression of **cardiac hypertrophy** comprising increasing CHAMP activity in heart cells of a subject.

91. A method of increasing exercise tolerance in a subject with heart failure or **cardiac hypertrophy** comprising increasing CHAMP activity in heart cells of a subject.

92. A method of reducing hospitalization in a subject with heart failure or **cardiac hypertrophy** comprising increasing CHAMP activity in heart cells of a subject.

93. A method of improving quality of life in a subject with heart failure or **cardiac hypertrophy** comprising increasing CHAMP activity in heart cells of a subject.

94. A method of decreasing morbidity in a subject with heart failure or **cardiac hypertrophy** comprising increasing CHAMP activity in heart cells of a subject.

95. A method of decreasing mortality in a subject with heart failure or **cardiac hypertrophy** comprising increasing CHAMP activity in heart cells of a subject.

112. The method of claim 105, wherein cardiac function is enhanced by

inhibition of **cardiac hypertrophy**.

L2 ANSWER 10 OF 10 USPATFULL on STN
AN 2002:272832 USPATFULL
TI Methods and compositions relating to muscle selective calcineurin interacting protein (MCIP)
IN Williams, R. Sanders, Dallas, TX, UNITED STATES
Rothermel, Beverly, Bedford, TX, UNITED STATES
PI US 2002150953 A1 20021017
AI US 2001-782953 A1 20010213 (9)
PRAI US 2000-216601P 20000707 (60)
DT Utility
FS APPLICATION
LREP Steven L. Highlander, Fulbright & Jaworski L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701
CLMN Number of Claims: 101
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 5727
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:
65. The method of claim 63, wherein said promoter is selected from the group consisting of myosin light chain-2 promoter, alpha actin promoter, troponin 1 promoter, Na.sup.+/Ca.sup.2+ exchanger promoter, dystrophin promoter, creatine kinase promoter, alpha7 integrin promoter, brain **natriuretic peptide** promoter, alpha B-crystallin/small heat shock protein promoter, alpha myosin heavy chain promoter and atrial natriuretic factor promoter.

77. A method of treating **cardiac hypertrophy** or heart failure comprising administering to a subject suffering from **cardiac hypertrophy** or heart failure an agent that promotes MCIP binding to calcineurin.

. . . chain-2 promoter, alpha actin promoter, troponin 1 promoter, Na.sup.+/Ca.sup.2+ exchanger promoter, dystrophin promoter, creatine kinase promoter, alpha7 integrin promoter, brain **natriuretic peptide** promoter, and alpha B-crystallin/small heat shock protein promoter, alpha myosin heavy chain promoter and atrial natriuretic factor promoter.

. . . chain-2 promoter, alpha actin promoter, troponin 1 promoter, Na.sup.+/Ca.sup.2+ exchanger promoter, dystrophin promoter, creatine kinase promoter, alpha7 integrin promoter, brain **natriuretic peptide** promoter, and alpha B-crystallin/small heat shock protein promoter, alpha myosin heavy chain promoter and atrial natriuretic factor promoter.

101. A method of treating **cardiac hypertrophy** or heart failure comprising administering to a subject suffering from **cardiac hypertrophy** or heart failure an agent that inhibits MCIP binding to calcineurin.

```
          207 CARDIAC (W) (HYPERTROPHY OR DISFUNCTION)
L2          10 (((NATRIURETIC (W) (RECEPTOR OR PEPTIDE)) OR ANP OR BNP) AND
               (CARDIAC (W) (HYPERTROPHY OR DISFUNCTION)))/CLM

=> d his

     (FILE 'HOME' ENTERED AT 13:58:36 ON 01 MAR 2005)

     FILE 'USPATFULL' ENTERED AT 13:58:50 ON 01 MAR 2005
L1          249 S ((NATRIURETIC (W) (RECEPTOR OR PEPTIDE)) OR ANP OR BNP) AND (
L2           10 S (((NATRIURETIC (W) (RECEPTOR OR PEPTIDE)) OR ANP OR BNP) AND
```